Characteristics of patients with Hepatitis B and C at Dr. Moewardi General Hospital in Surakarta, Indonesia

Benedictus Aditya Satya Laksana Adji; Triyanta Yuli Pramana; Tri Nugraha Susilawati

doi:10.19106/JMedSci005403202207

Characteristics of patients with Hepatitis B and C at Dr. Moewardi General Hospital in Surakarta, Indonesia

https://doi.org/10.19106/JMedSci005403202207

Benedictus Aditya Satya Laksana Adji⁽¹⁾, Triyanta Yuli Pramana⁽²⁾, Tri Nugraha Susilawati^(3*)

(1) Faculty of Medicine, Universitas Sebelas Maret, Surakarta
(2) Department of Internal Medicine, Dr. Moewardi Hospital/ Faculty of Medicine, Universitas Sebelas Maret, Surakarta
(3) Department of Microbiology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta
(*) Corresponding Author

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain a significant health burden in the world, which is mainly attributed to patients who develop chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The epidemiology of hepatitis B and C in Surakarta, Central Java Province, Indonesia has never been reported. This study aimed to investigate the demographic, clinical, and laboratory characteristics of patients with hepatitis B and C who were admitted to Dr. Moewardi General Hospital, Surakarta in 2019. The medical records of patients with hepatitis B (n=94) and hepatitis C (n=75) were examined, and the data were analyzed using the chi-square and Mann-Whitney tests. The patients with hepatitis C were generally older, more likely to develop jaundice and ascites, and had higher levels of serum urea, creatinine, AST, and total bilirubin compared to those with hepatitis B. In conclusion, patients with HCV infection had worse clinical presentation and laboratory profiles than those with HBV infection. However, further research is needed on a wider scale to confirm this result.

Keywords

hepatitis B; hepatitis C; HBV; HCV; epidemiology

Full Text:

PDF

References

Muljono DH. Epidemiology of hepatitis B and C in Republic of Indonesia. Euroasian J Hepatogastroenterol 2017; 7(1):55-9.
https://doi.org/10.5005/jp-journals-l0018-1212
2.World Health Organization. Hepatitis C [Internet]. WHO 2020 [cited 31 August 2020]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
3.Sinn DH, Cho EJ, Kim JH, Kim DY, Kim YJ, Choi MS. Current status and strategies for viral hepatitis control in Korea. Clin Mol Hepatol 2017; 23(3):189-95.
https://doi.org/10.3350/cmh.2017.0033
4.Yano Y. Hepatitis B virus infection in Indonesia. World J Gastroenterol 2015; 21(38):10714-20.
https://dx.doi.org/10.3748/wjg.v21.i38.10714
5.Wait S, Kell E, Hamid S, Muljono D, Sollano J, Mohamed R et al. Hepatitis B and hepatitis C in southeast and southern Asia: Challenges for governments. Lancet Gastroenterol Hepatol 2016; 1(3):248-55.
https://doi.org/10.1016/S2468-1253(16)30031-0
6.Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, et al. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med 2011; 12(3):159-64.
http://dx.doi.org/10.1007/s10238-011-0160-7
7.Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29):9633-52.
https://doi.org/10.3748/wjg.v20.i29.9633
8.Botros M, Sikaris KA. The de Ritis ratio: the test of time. Clin Biochem Rev 2013; 34(3):117-30.
9.Kolou M, Katawa G, Salou M, Gozo-Akakpo KS, Dossim S, Kwarteng A, et al. High prevalence of hepatitis B virus infection in the age range of 20-39 years old individuals in Lome. Open Virol J 2017; 11(1):1-7.
https://doi.org/10.2174/1874357901710011001
10.Simoes P, Asaad A, Abed J, Engelson ES, Kotler DP. Effect of gender on the Response to hepatitis C treatment in an inner-city population. Women's Health Issues 2015; 25(3):289-93.
https://doi.org/10.1016/j.whi.2015.02.008
11.The Korean Association for the Study of the Liver. KASL clinical practice guidelines: Management of hepatitis C. Clin Mol Hepatol 2014; 20(2):89-136.
https://doi.org/10.3350/cmh.2014.20.2.89
12.Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol 2012; 12:64.
https://doi.org/10.1186/1471-230x-12-64
13.Mani SKK, Andrisani O. Hepatitis B virus-associated hepatocellular carcinoma and hepatic cancer stem cells. Genes 2018; 9(3):137.
https://doi.org/10.3390/genes9030137
14.Sinn DH, Gwak G, Cho J, Paik SW, Yoo BC. Comparison of clinical manifestations and outcomes between hepatitis B virus-and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One 2015; 10(1):e0116652.
https://doi.org/10.1371/journal.pone.0112184
15.Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol 2015; 21(2):105-14.
https://doi.org/10.3350/cmh.2015.21.2.105
16.Muhie OA. Causes and clinical profiles of ascites at University of Gondar Hospital, Northwest Ethiopia: Institution-based cross-sectional study. Can J Gastroenterol Hepatol 2019; 2019:5958032.
https://doi.org/10.1155/2019/5958032
17.Shah R, John S. Cholestatic jaundice. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
https://www.ncbi.nlm.nih.gov/books/NBK482279/
18.Seki M, Nakayama M, Sakoh T, Yoshitomi R, Fukui A, Katafuchi E, et al. Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3-5 chronic kidney disease: a prospective observational study. BMC Nephrol 2019; 20(1):115.
https://doi.org/10.1186/s12882-019-1306-1
19.Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep 2017; 5(2):127-37.
https://doi.org/10.1093/gastro/gox009
20.Azmi AN, Tan S, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol 2015; 7(1):78-92.
https://doi.org/10.4254/wjh.v7.i1.78
21.Dashti-Khavidaki S, Khalili H, Nasiri-Toosi M. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors. Expert Rev Clin Pharmacol 2018; 11(5):525-9.
https://doi.org/10.1080/17512433.2018.1451327
22.Goel A, Bhadauria D, Aggarwal R. Hepatitis C virus infection and chronic renal disease: A review. Indian J Gastroenterol 2018; 37(6):492-503.
https://doi.org/10.1007/s12664-018-0920-3
23.Rinonce H, Yano Y, Utsumi T, Heriyanto D, Anggorowati N, Widasari D, et al. Hepatitis B and C virus infection among hemodialysis patients in Yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission. J Med Virol 2013; 85(8):1348-61.
https://doi.org/10.1002/jmv.23581
24.Mastoi A. Metabolic investigations in patients with hepatitis B and C. World J Gastroenterol 2010; 16(5):603-7.
https://doi.org/10.3748/wjg.v16.i5.603
25.Shahid M, Idrees M, Nasir B, Raja A, Raza S, Amin I, et al. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. Eur J Gastroenterol Hepatol 2014; 26(7):788-94.
https://doi.org/10.1097/MEG.0000000000000109
26.Hall P, Cash J. What is the real function of the liver 'function' tests?. Ulster Med J 2012; 81(1):30-6.

DOI: https://doi.org/10.19106/JMedSci005403202207

Article Metrics

Abstract views : 397 |

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View My Stats

Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jurnal.ugm.ac.id/bik/.

Username
Password
Remember me